HBV状态调节HIV感染者从TDF转换为TAF后的转氨酶下降
这项纵向观察性研究纳入727例从TDF转换为TAF的HIV感染者,其中7%为慢性乙肝、35%为可能的隐匿性HBV感染。转换后ALT显著下降,且慢性乙肝者的下降幅度更大;同时观察到体重增加加快和肝脂肪变指数先短暂下降后逐年上升。
要点
- HIV感染者从TDF转换为TAF后ALT平均下降3.5 UI/mL,慢性乙肝者下降更明显。
- 可能的隐匿性HBV感染对ALT下降的影响不显著。
- 转换为TAF后体重增加加快,肝脂肪变指数先降后升,需监测代谢变化。
核心结论
- 从TDF转换为TAF与HIV感染者ALT适度但显著的下降相关,在HBsAg阳性者中尤为明显。
- TAF可能对该亚组是有利选择,但潜在的代谢后果需要密切监测。
研究设计与样本
- 纵向观察性研究,纳入2016至2023年间从TDF转换为TAF的HIV感染者727例。
- 采用随机截距混合效应模型评估转换对转氨酶的影响,并纳入HBV状态交互项。
主要发现
- 转换至TAF与ALT显著下降相关(β -3.5 UI/mL,95%CI:-5.2至-1.9)。
- 与HBV阴性者相比,慢性乙肝者ALT下降更陡(β -7.5,95%CI:-11.8至-3.2)。
- 可能的隐匿性HBV感染与ALT下降无显著相关(β -1.9;95%CI:-4.4至0.6;P=0.133)。
- TAF与体重增加加速相关(+0.75 kg/年,95%CI:0.63至0.87)。
- 肝脂肪变指数短暂下降(-0.22;95%CI:-0.38至-0.06),随后每年上升(+0.18/年;95%CI:0.10至0.27)。
临床怎么用
- HIV感染者从TDF转换为TAF后应关注ALT变化,尤其HBsAg阳性者可能获益更明显。
- 转换后需监测体重和肝脂肪变指数等代谢指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) has been associated with reduced transaminase level among people with HIV (PWH), with and without HBV. It is unclear whether the effect is mediated by HBV serostatus. METHODS: We conducted a longitudinal observational study of PWH who switched from TDF to TAF between 2016 and 2023. A mixed-effects model with random intercepts assessed the effect of the switch on transaminases, including an interaction term for HBV status: chronic hepatitis B (HBsAg+), possible occult HBV infection (pOBI; HBsAg-/HBcAb+) and no HBV. RESULTS: Among 727 individuals, 7% had chronic hepatitis B and 35% had pOBI. Switching to TAF was associated with a significant ALT decrease (β -3.5 UI/mL, 95%CI: -5.2 to -1.9). Compared to HBV-negative individuals, individuals with chronic hepatitis B experienced steeper ALT reduction (β -7.5, 95%CI: -11.8 to -3.2), while pOBI was associated with a non-significant reduction (β -1.9; 95%CI: -4.4-0.6; P = 0.133). These findings persisted after adjusting for other predictors of transaminase levels. TAF was also associated with accelerated weight gain (+0.75 kg/year, 95% CI: 0.63-0.87) and a transient drop in the Hepatic Steatosis Index (-0.22; 95% CI: -0.38 to -0.06) followed by an annual increase thereafter (+0.18/year; 95% CI: 0.10-0.27). CONCLUSIONS: Switching from TDF to TAF is associated with modest but statistically significant ALT reduction in PWH, especially in HBsAg + individuals. Our findings suggest that TAF may represent a favourable option in this subgroup, although potential metabolic consequences warrant close monitoring.
引用
- Lapadula G, Soria A, Antolini L, et al. HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV. J Antimicrob Chemother. 2026. PMID: 41665334. doi:10.1093/jac/dkag045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。